Pharmaceutical compositions of nilotinib

US12403140B2 · kind B2 · utility

Assignee

• AZURITY PHARMACEUTICALS, INC. · US

Inventors

• Paras P. JAIN · Amravati, IN
• Ajay Singh · Princeton, US
• Keerthi Priya · Ghanpur, IN
• Girish Kumar Jain · Ashti, IN
• Girish G. Kore · Jamkhed, IN
• Sandeep Jain · Milpitas, US
• Hanimi Reddy Bapatu · Hyderabad, IN

Key dates

• Filing date: Sep 15, 2023
• Grant date: Sep 2, 2025
• Expiry date: Oct 5, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/4866
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.